FDX1 and hepatocellular carcinoma: When HCC patients were categorized into two groups based on the best cutoff value of the expression of FDX1 in TCGA-LIHC dataset, about 58% (212/365) of them were labeled as high-FDX1 and exhibited a significantly longer survival time than that of the remaining low-FDX1 HCC patients (Figure 1H, p = 0.016).